ERAS 10-Q: SEC filing
Erasca, Inc.
Filed with the SEC on · accession 0001193125-26-458289
ERAS filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -5.0% by the first close after the filing.
Summary of the filing
Erasca, Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2026, reporting routine financial results and disclosures including cash position, investments, and equity activity.
Key details
How ERAS stock reacted
Close before
$16.80
Nov 11, 2026
First close after
-4.97%
$15.96
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ERAS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ERAS?
Click hereFrequently asked questions
What did ERAS file with the SEC on Nov 12, 2026?
ERAS filed a 10-Q (SEC filing). Erasca, Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2026, reporting routine financial results and disclosures including cash position, investments, and equity activity.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did ERAS stock react to this filing?
ERAS closed at $16.80 before the filing and $15.96 on Nov 12, 2026 (-4.97%).
Other ERAS SEC filings
- 8-K · Executive departureOct 16, 2026
- 8-K · SEC filingAug 24, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- 10-Q · SEC filingAug 11, 2026
- 8-K · SEC filingAug 11, 2026
- 8-K · Executive departureAug 10, 2026
- 8-K · Secondary offeringJul 14, 2026
- 424B5 · Secondary offeringJul 14, 2026
- 424B5 · Secondary offeringJul 13, 2026
- 8-K · Fda approvalJul 13, 2026
Get alerts when ERAS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days